Iricryn (Bimatoprost)

Bimatoprost activates prostaglandin F (FP) receptors in the eye’s ciliary body, which increases the uveoscleral outflow of aqueous humor. This enhanced drainage lowers the volume of fluid in the anterior chamber, thereby decreasing intraocular pressure.

The dosing regimen for Iricryn is determined by the prescribing ophthalmologist. Typically, a single drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and frequency must follow the clinician’s instructions.

Safety data for bimatoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To request Iricryn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iricryn (bimatoprost) belongs to the prostaglandin analog class, which generally offers potent IOP‑lowering effects with once‑daily dosing. Compared with beta‑blocker drops, prostaglandin analogs often achieve greater pressure reduction and have a different side‑effect profile, such as eyelash growth and peri‑ocular pigmentation.

Iricryn should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct sunlight and moisture, and discard any solution that appears discolored or contains particles.

Iricryn is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac of the prescribed eye(s). Avoid touching the tip of the bottle to the eye or any surface.

Serious but rare risks include uveitis, macular edema, significant iris or peri‑ocular pigmentation changes, and severe allergic reactions. Any sudden vision loss, eye pain, or marked redness should prompt immediate medical evaluation.

Iricryn is contraindicated in patients with known hypersensitivity to bimatoprost or any component of the formulation. It should also be avoided in individuals with active ocular inflammation, such as uveitis, and in those using other prostaglandin analog eye drops without medical supervision.